GlobeNewswire

New Predictive Analytics, Assurance Capabilities Advance Cisco's Strategy to Reinvent the Network for Digital Business

Dela
  • Mathematical modeling and contextual insights represent the next major advancement in intent-based networking revolution
  • Waves of software innovation fuel evolution of networking portfolio toward subscription-led model
  • Cisco delivers an industry leading end-to-end intent-based networking portfolio, which spans the data center, campus, branch and edge

BARCELONA, Spain, Jan. 30, 2018 (GLOBE NEWSWIRE) -- Cisco today announced powerful assurance innovations across its intent-based networking portfolio that will help IT teams shift from reactive to proactive. It will address the 43 percent of time IT spends troubleshooting, while making IT operations more proactive, agile and automated. The software innovations represent significant advancements in mathematical modeling and contextual insights, accelerating Cisco's strategy to reinvent the network for the digital era.

Over the past few years, the explosion of devices, adoption of cloud, and exponential growth of security threats have challenged current approaches for building and managing networks. Cisco's vision is to create a network that anticipates operational issues, stops security threats in their tracks, and continues to learn, adapt and protect. To realize this, Cisco is driving the intent-based networking revolution by transforming the entire network, from the data center and campus, to the branch and edge.

Today, Cisco is introducing its second wave of intent-based networking innovation, with powerful assurance products spanning the networking portfolio. 

  • In the data center, the Cisco Network Assurance Engine uses continuous verification of the entire network to help keep business running as intended, even as the network changes dynamically.
  • In campus and branch networks, Cisco DNA Center Assurance is delivering a new level of insight and visibility to dramatically reduce the time and money IT spends troubleshooting across wired and wireless environments.
  • And, for customers with distributed IT operations, the new Cisco Meraki Wireless Health reduces mean time to remediate wireless issues with rich analytics and insights.

"The network has never been more critical to business success," said David Goeckeler, executive vice president, Networking and Security Business at Cisco. "We're reinventing the network ground up to deliver a secure and intelligent platform for digital business. Today, we are taking another major step toward that ambitious goal with intent-based networking innovations designed to deliver contextual insights and assurance that will help transform IT from reactive to proactive."

Cisco's intent-based networking portfolio represents a fundamental shift away from the manual and time-intensive methods by which networks are traditionally managed. These intent-based networks capture and translate business intent into network policies, and activate them across the infrastructure. With the introduction of assurance capabilities, they can now continuously verify the network is operating as intended.

Customers globally are embracing intent-based networking. Nearly 200 customers are in early field trails with the new assurance technologies, including Robert Bosch GmbH, REWE Group, Houston Methodist Hospital and Scotiabank. More than 1,100 customers are deploying the recently announced Catalyst 9000 Series switches, with 150 running DNA Center pilots. In the data center, Cisco has more than 14,500 Nexus 9000 customers, with a 45 percent ACI attach rate.

Innovation Spanning Data Center and Enterprise Networking 
Today, Cisco is introducing three powerful new assurance products that further demonstrate how intent-based networking systems move at the speed of digital business.

In the data center network, Cisco is enabling always-on assurance through the Cisco Network Assurance Engine. By combining mathematically accurate models of the network with more than 30 years of codified domain knowledge, Cisco provides IT teams the ability to instantly pinpoint why and when the network is not acting as intended, then offer suggestions on how to address the issue. This comprehensive view into their network helps enable IT teams to:

  • Predict the Impact of Changes: Make changes to the network faster and with more confidence, catching human configuration errors before they cause problems.
  • Continuously Verify Network Behavior: Proactively eliminate network outages and vulnerabilities by continuously analyzing the state of the entire network.
  • Assure Security Policy and Compliance: Reduce risk by assuring that security policies are being applied consistently across the network, and ensure policies are compliant with business requirements-every minute of every day.

With ACI and Tetration, Cisco provides the ability to translate application intent and activate those policies across the network. Now, with the Network Assurance Engine, Cisco is delivering the final element of intent-based networking - the assurance of intent.

In the campus and branch, Cisco is enabling 'everything as a sensor' and aggregating intelligence from the network, application, client and things to help provide IT with full context. These capabilities will dramatically reduce the 43 percent of time that IT spends troubleshooting and improve the experience for employees and customers.

Cisco DNA Center Assurance provides a 360-degree contextual view that connects all the relationships of who, what, where, when, how. Spanning wired and wireless environments, it delivers a complete picture of what is happening between users and applications with real-time, historical and predictive capabilities. DNA Center Assurance helps IT teams address three major issues:

  • Problem Isolation: Get to the root cause in minutes-not days or weeks-by isolating where exactly the issue happened.
  • Problem Replication: Go back in time to when an issue occurred. IT can view a complete 360 snapshot of the status of the network, user, device and application at the exact moment the issue arose.
  • Problem Resolution: Proactively fix the issue through guided remediation.

With Cisco Meraki Wireless Health, IT also gains visibility and rich analytics to troubleshoot wireless issues faster and deliver a better user experience. Cisco Meraki uses a cloud-managed IT model to automate operations, simplifying the complexity of IT. Now, Meraki Wireless Health allows IT teams to quickly identify wireless anomalies, find poorly performing access point and clients, and provide actionable insights to improve the wireless experience.

Powered by network analytics and rich contextual data, Cisco Services offers new services to help customers streamline the deployment of the new assurance solutions. From advisory and implementation, through optimization and managed services, Cisco and its partners are helping customers accelerate their journey to truly intent-based networks.

Customer Quotes
Robert Bosch GmbHJan Holzmann, Team Lead for Data Center Network Operations
"We are constantly bringing on new applications and expanding our data center capacity as we expand our business. The Cisco Network Assurance Engine helps enable a new level of quality for our application migrations. With a detailed understanding of the policy model and proactive verification of all changes, Cisco Network Assurance Engine can help us greatly reduce the risk of production outages and accelerate our timelines."

Houston Methodist Hospital, Manuel Ortiz III, Senior Wireless Engineer
"DNA Center helps me find problems proactively, before users contact me. With a mostly wireless network, I'm able to find devices throughout the network and quickly solve any problems with the help of analytics."

Axians Nordic, Erik Sohlman, Senior Manager and CTO
"As a Cloud Service Provider, our business depends on network availability and delivering on customer SLAs. We are always looking for modern technologies to manage our multiple data centers and remain an industry leader.  Cisco Network Assurance Engine's approach of 'always on assurance' for our network and services will make our operating model more proactive and help enable us to remain as the best-in-class service provider to our customers."

REWE Group, Hans Vasters, Senior Network Architect
"Cisco DNA Center allows the networking team to focus on our core projects and give more responsibility to the first line support team. It lets our team be proactive when it comes to resolving issues, before it becomes a problem to our users."

Scotiabank, Nicholas Yurkovich Chief Network Engineer
"The more intuitive that I can make troubleshooting, the sooner I can take the network out of the equation. With Cisco DNA Center Assurance, the Scotiabank first line support teams can now take a proactive approach to resolving wireless issues and the engineering networking teams can work on growth and forward-looking opportunities."

West Corporation, Tania Mazza, Director, Network Engineering
"At West, we run critical communications infrastructure for our customers, and as such, scale and speed are vital for our operations. Using the change verification process, we see Cisco Network Assurance Engine as a way to achieve higher levels of automation with increased certainty, allowing us to confidently move at a faster pace."

Availability

  • The Cisco Network Assurance Engine is available now, initially for Cisco ACI customers, with a free, 30-day, no-commitment trial. Customers can purchase it via software subscription.
  • Cisco DNA Center Assurance is available now. Customers can purchase it via the Cisco ONE subscription offer for networking.
  • Cisco Meraki Wireless Health is expected to be available in early 2018. It will be included with the standard subscription for Meraki Wireless Access Points.

Additional Resources

About Cisco
Cisco (NASDAQ:CSCO) is the worldwide technology leader that has been making the Internet work since 1984. Our people, products, and partners help society securely connect and seize tomorrow's digital opportunity today. Discover more at newsroom.cisco.com and follow us on Twitter at @Cisco.

Cisco and the Cisco logo are trademarks or registered trademarks of Cisco and/or its affiliates in the United States and certain other countries. A listing of Cisco's trademarks can be found at  www.cisco.com/go/trademarks .  All other trademarks mentioned are the property of their respective owners. The use of the word partner does not imply a partnership relationship between Cisco and any other company. Many of the products and features described herein remain in varying stages of development and will be offered on a when-and-if-available basis. This roadmap is subject to change at the sole discretion of Cisco, and Cisco will have no liability for delay in the delivery or failure to deliver any of the products or features set forth in this document. This document is Cisco Public Information.

RSS Feed for Cisco: http://newsroom.cisco.com/rss-feeds

Gareth Pettigrew
Cisco
+1 (604) 647-2326 
gpettigr@cisco.com

Lee Davis                                                                                              
Cisco                                                                                                           
650-868-3036                                                                                                                    
leedavis@cisco.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cisco via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics appoints a new Chief Medical Officer25.3.2019 11:00:00 CETPressmeddelande

STOCKHOLM, March 25, 2019. Karolinska Development's portfolio company Aprea Therapeutics announces today that Dr. Eyal C. Attar has been appointed to a position as Senior Vice President and Chief Medical Officer (CMO). Dr. Attar joins Aprea from Agios Pharmaceuticals, where he was Senior Medical Director and IDH Hematology Medical Lead. Having served at Agios since 2014, Dr. Attar played a leadership role in the clinical development and approval of Idhifa and Tibsovo for patients with relapsed/refractory Acute Myeloid Leukemia (AML). Prior to Agios, he served on the clinical staff at the Massachusetts General Hospital Cancer Center, where Dr. Attar was a member of the Center for Leukemia and Assistant Professor of Medicine at Harvard Medical School. "Dr. Attar's deep medical and biotech industry experiences will strengthen our clinical development efforts as we continue to advance our first-in-class p53 reactivating agents in late-stage clinical studies", states Christian S. Schade, Pr

Karolinska Development's portfolio company Aprea Therapeutics appoints a new Chief Medical Officer25.3.2019 11:00:00 CETPressmeddelande

STOCKHOLM, March 25, 2019. Karolinska Development's portfolio company Aprea Therapeutics announces today that Dr. Eyal C. Attar has been appointed to a position as Senior Vice President and Chief Medical Officer (CMO). Dr. Attar joins Aprea from Agios Pharmaceuticals, where he was Senior Medical Director and IDH Hematology Medical Lead. Having served at Agios since 2014, Dr. Attar played a leadership role in the clinical development and approval of Idhifa and Tibsovo for patients with relapsed/refractory Acute Myeloid Leukemia (AML). Prior to Agios, he served on the clinical staff at the Massachusetts General Hospital Cancer Center, where Dr. Attar was a member of the Center for Leukemia and Assistant Professor of Medicine at Harvard Medical School. "Dr. Attar's deep medical and biotech industry experiences will strengthen our clinical development efforts as we continue to advance our first-in-class p53 reactivating agents in late-stage clinical studies", states Christian S. Schade, Pr

Immunicum AB (publ) meddelar kommande konferenser i mars och april22.3.2019 08:00:00 CETPressmeddelande

Pressmeddelande 22 mars 2019 Immunicum AB (publ) meddelar kommande konferenser i mars och april Immunicum AB (publ; IMMU.ST) meddelar idag att medlemmar av ledningsgruppen kommer att delta och presentera vid kommande konferenser i mars och april. BIO-Europe Spring Datum: 25-27 mars 2019 Plats: Messe Wien Exhibition and Congress Center, Wien, Österrike Deltagare: Sijme Zeilemaker China Focus @ Europe Vienna Datum: 27 mars 2019 Paneltid/Sessionstid: 16.10 - 17.00, Panel 4: Partnering Opportunities with Chinese Pharma Plats: Hilton Vienna Danube Waterfront, Wien, Österrike Deltagare: Carlos de Sousa Swedish American Life Science Summit 2019 Datum: 9-10 april 2019 Presentationsdatum: Onsdagen 10 april 2019 Plats: House of Sweden, 2900 K St. NW, Washington D.C. 20008 Deltagare: Carlos de Sousa För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 8 732 8400 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@i

Immunicum AB (publ) Announces Upcoming Conferences in March and April22.3.2019 08:00:00 CETPressmeddelande

Press Release 22 March 2019 Immunicum AB (publ) Announces Upcoming Conferences in March and April Immunicum AB (publ; IMMU.ST) announced today that members of the management team will attend and present at upcoming conferences in March and April. BIO-Europe Spring Date: March 25-27, 2019 Venue: Messe Wien Exhibition and Congress Center, Vienna, Austria Participant: Sijme Zeilemaker China Focus @ Europe Vienna Date: March 27, 2019 Panel Time/Session: 16.10 - 17.00, Panel 4: Partnering Opportunities with Chinese Pharma Venue: Hilton Vienna Danube Waterfront, Vienna, Austria Participant: Carlos de Sousa Swedish American Life Science Summit 2019 Date: April 9-10, 2019 Presentation Date: Wednesday, April 10, 2019 Venue: House of Sweden, 2900 K St. NW, Washington D.C. 20008 Participant: Carlos de Sousa For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 8 732 8400 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir

Karolinska Development's portfolio company Promimic announces partnership with Onkos Surgical15.3.2019 08:45:00 CETPressmeddelande

STOCKHOLM, March 15, 2019. Karolinska Development's portfolio company Promimic announces a new partnership with the U.S company Onkos Surgical® to commercialize Promimic's proprietary Hydroxyapatite (HA) Surface Technologies in Limb Salvage Surgery. Promimic develops and markets products within nano-materials for innovative surface treatments and has developed the HA nano Surface that is clinically proven to speed up and improve the anchoring of implants in bone. The innovative technology is already licensed to several dental implant companies. The partnership with Onkos Surgical®, a U.S company addressing the clinical challenges associated with tumor surgery, represents an important step into the orthopaedic space. The partnership will focus on combining Promimic's HA nano Surface Technology with Onkos Surgical®'s ELEOS Limb Salvage Portfolio. Implant failure due to aseptic loosening remains one of the key challenges associated with limb salvage surgery. With HA nano Surface, Onkos Su

Karolinska Development's portfolio company Promimic announces partnership with Onkos Surgical15.3.2019 08:45:00 CETPressmeddelande

STOCKHOLM, March 15, 2019. Karolinska Development's portfolio company Promimic announces a new partnership with the U.S company Onkos Surgical® to commercialize Promimic's proprietary Hydroxyapatite (HA) Surface Technologies in Limb Salvage Surgery. Promimic develops and markets products within nano-materials for innovative surface treatments and has developed the HA nano Surface that is clinically proven to speed up and improve the anchoring of implants in bone. The innovative technology is already licensed to several dental implant companies. The partnership with Onkos Surgical®, a U.S company addressing the clinical challenges associated with tumor surgery, represents an important step into the orthopaedic space. The partnership will focus on combining Promimic's HA nano Surface Technology with Onkos Surgical®'s ELEOS Limb Salvage Portfolio. Implant failure due to aseptic loosening remains one of the key challenges associated with limb salvage surgery. With HA nano Surface, Onkos Su

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum